Share this article:

Lombard Medical Inc., a British medical device maker with U.S. headquarters in Irvine, has filed a registration statement with the Securities and Exchange Commission for an $80 million initial public offering on the Nasdaq exchange.

Lombard makes endovascular stent grafts for treating aortic aneurysms, or a ballooning of the body’s main artery. Its lead device, Aorfix, has Food and Drug Administration approval.

Get the latest OC business and Coronavirus updates

It said in its prospectus that its shares already trade on AIM, a market operated by the London Stock Exchange plc.

The company said it would use proceeds of the offering to double its domestic sales force and to develop a thoracic stent graft device, among other things.